Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Mordchai Ravid"'
Publikováno v:
Diabetes Care
Diabetes Care, 34, S325-S329. AMER DIABETES ASSOC
Diabetes Care, 34, S325-S329. AMER DIABETES ASSOC
It is beyond doubt that patients with diabetes are at high risk of developing renal and cardiovascular disease. Both outcomes have significant clinical implications and are associated with high additional costs. Several traditional (blood pressure, H
Publikováno v:
Kidney International. 69(11):2057-2063
We described the characteristics in a referred cohort of type II diabetic patients in the Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes study evaluating the global prevalence and determinants of m
Autor:
Rita Rachmani, Mordchai Ravid
Publikováno v:
European Journal of Internal Medicine. 16:154-159
Diabetes mellitus is rapidly evolving as the epidemic of the 21st century. The presently estimated number of 190 million is predicted to grow to over 300 million by the year 2025. Cardiovascular (CVD) morbidity and mortality is two to five times high
Publikováno v:
Diabetes, Obesity and Metabolism. 6:63-68
Aim: Acarbose, a glucose oxidase inhibitor, delays the absorption of glucose thus reducing post-prandial blood glucose level, haemoglobin A1c (HbA1c) and insulin resistance in patients with diabetes mellitus and in subjects with impaired glucose tole
Autor:
Mordchai Ravid
Publikováno v:
Polish Archives of Internal Medicine. 122:65-67
Autor:
Zohar Levy, Ayana Dvir, Dror Harats, Svetlana Trestman, Rita Rachmani, Mordchai Ravid, Aviv Shaish
Publikováno v:
European Journal of Internal Medicine. 14:479-483
Background: Solid evidence suggests that atheroscleosis is associated with immune reactions. Most of the activated T cells in the plaque are T helper 1 subtype (Th1), which secrete interferon-gamma (IFN-gamma), now generally accepted as a proatheroge
Autor:
Ayana Dvir, Hana Levkovietz, Dror Harats, Mordchai Ravid, Rita Rhachmani, Svetlana Trestman, Hofit Cohen, Aviv Shaish, Zohar Levy
Publikováno v:
International Journal of Experimental Diabesity Research
Omapatrilat inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). ACE inhibitors have been shown to inhibit atherosclerosis in apoE-deficient mice and in several other animal models but failed in low-density lipoprotein (
Autor:
Hana Levkovitz, N. Yacov, A. Shaish, Ayana Dvir, Dror Harats, S. Trestman, R. Rhachmani, Mordchai Ravid, Z. Levi, Hofit Cohen, Yariv Gerber
Publikováno v:
Diabetes, Obesity and Metabolism. 5:45-50
BACKGROUND The administration of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists to low-density lipoprotein (LDL)-receptor-deficient mice resulted in a reduction in the atherosclerotic lesion area in male mice, but not in female
Publikováno v:
European Journal of Internal Medicine. 13:428-433
BACKGROUND: The strict limiting criteria for the use of metformin in diabetes mellitus stem largely from reports, in the 1970s, of mortality and lactic acidosis associated with phenformin. Data about metformin are less clear and are based mainly on c
Publikováno v:
Clinical Pharmacology & Therapeutics. 72:302-307
Objectives Lipoprotein oxidation, dyslipidemia, and hypertension are important underlying causes of accelerated atherosclerosis in patients with diabetes mellitus. The potential of antihypertensive medications to reduce lipid oxidation is, therefore,